The FDA granted Investigational New Drug (IND) approval for MSA treatment on August 11, 2025. Vikram Khurana commented on this approval.
2 reports, 1 independent
Updated Aug 11
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted Investigational New Drug (IND) approval for MSA treatment on August 11, 2025. Vikram Khurana commented on this approval.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The FDA placed a clinical hold on the IND application for the company Aardvark.
- Takeda announced FDA approval of its drug MIMRYLO, a decision supported by VERIFY results.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- NewcelX Ltd. advanced its IND-enabling work for a Phase 1/2a trial and held a successful Type B Pre-IND meeting with the FDA.
- Experimental therapies require approval from the FDA.
Coverage
Newest first; wire copies grouped- GlobeNewswireFDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biote
- GlobeNewswireFDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older Proven efficacy across all three key markers of disease—68% reduction in prote